Literature DB >> 3288031

Maximally reducing cardiovascular risk in the treatment of hypertension.

N M Kaplan1.   

Abstract

With the increasing recognition of relatively mild hypertension, asymptomatic patients are being started on life-long therapy with antihypertensive agents. Before the diagnosis is made or therapy instituted, elevated blood pressure must be verified. To provide maximal protection against premature cardiovascular disease and coronary disease, various non-drug therapies should be used that lower both blood pressure and other risk factors. Drugs should be chosen to provide maximal efficacy, long-term safety, and multifaceted convenience, providing the greatest protection with the least interference with quality of life. These goals can be best achieved by substituting commonly used drugs such as diuretics, central agonists, and beta-blockers with vasodilators, such as alpha-blockers, angiotensin-converting enzyme inhibitors, and calcium blockers.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3288031     DOI: 10.7326/0003-4819-109-1-36

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  4 in total

Review 1.  Reserpine: a relic from the past or a neglected drug of the present for achieving cost containment in treating hypertension?

Authors:  G J Magarian
Journal:  J Gen Intern Med       Date:  1991 Nov-Dec       Impact factor: 5.128

Review 2.  Safety considerations in treating concomitant diseases in patients with asthma.

Authors:  L W Hunt
Journal:  Drug Saf       Date:  1998-05       Impact factor: 5.606

Review 3.  What do you do when the blood pressure is up? An approach to the known hypertensive who has an elevated blood pressure.

Authors:  R L Schiff; M H Cohen; A Balson
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

4.  The phosphatidylcholine transfer protein StarD7 is important for myogenic differentiation in mouse myoblast C2C12 cells and human primary skeletal myoblasts.

Authors:  Yasuhiro Horibata; Satomi Mitsuhashi; Hiroaki Shimizu; Sho Maejima; Hirotaka Sakamoto; Chieko Aoyama; Hiromi Ando; Hiroyuki Sugimoto
Journal:  Sci Rep       Date:  2020-02-18       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.